DF/HCC New Member

Please welcome Dr. Guerriero who recently joined DF/HCC, and is a member of the Breast Cancer Program.

 

Transcript:

My name is Jennifer Guerriero, and I am an Assistant Professor in the Department of Surgery, Division of Breast Surgery at Brigham and Women’s Hospital, where my lab is located. I also serve as the Director of the Breast Tumor Immunology Laboratory at Dana-Farber Cancer Institute. I recently joined the Dana-Farber/Harvard Cancer Center Breast Cancer Program.

The overall goal of my lab is to accelerate breast cancer immunotherapy through harnessing tumor associated macrophages. We are working to designing clinically effective strategies to promote T-cell activation and weaken the immune-suppressive tumor microenvironment to improve immunotherapy response rates in breast cancer patients. To do this our work involves identifying tumor-promoting macrophages in breast tumors before and after therapy, elucidating their molecular and metabolic regulation that promotes immune suppression and therapy-resistance and determining how tumor macrophage phenotype, metabolism and function, among other things, can be modulated for anti-tumor responses.

Our work focuses on in-depth analysis of animal models and patient samples. In this regard, we work closely with the Breast Oncology Program and Breast Tumor Immunology Laboratory (BTIL) at Dana-Farber Cancer Institute to perform translational research aimed at elucidating the immune regulation of breast cancer. 

Additionally, the Guerriero Lab is highly integrated into the Laboratory of Systems Pharmacology at Harvard Medical School where we utilize a number of cutting edge, sophisticated analysis platforms to interrogate the tumor microenvironment at a single cell level to resolve both spatial and transcriptomic features of tumor macrophages. We think that deep understanding of tumor macrophage biology and function will create new opportunities to harness macrophages for anti-cancer therapy. Targeting both innate and adaptive immunity is likely to be the optimal strategy for anti-cancer therapy and we think this work is particularly important in breast cancer given the low response rates to date of T-cell immunotherapy and abundance to macrophages in breast tumors.

I believe team science is the only way to move forward to cure breast cancer and we are always open to new collaborations.